Principles of Chemotherapy
Grace K. Dy and Alex A. Adjei uring World War II, sailors who were accidentally exposed to nitrogen mustard following the explosion of a ship developed marrow and lymphoid hypoplasia.
1 This serendipitous discovery led to the first clinical trial conducted in 1942 using nitrogen mustard in patients with malignant lymphomas at Yale University.
2 This marked the beginning of a new era of research in the quest for effective and safe drugs used in cancer chemotherapy.
The term chemotherapy has been loosely applied to the myriad systemic therapeutic options in cancer treatment exclusive of irradiation and surgical approaches. In this chapter, we confine our discussion of chemotherapy to refer to the use of conventional cytotoxic agents. Use of targeted and biologic agents such as hormone or signal transduction manipulation and gene therapy is explored in other chapters.
Cancer Cell Population Kinetics
The discussion that follows briefly describes the various paradigms of tumor growth and response to cytotoxic agents to facilitate understanding of the rationale and basis for the approaches to cancer therapy with cytotoxic agents.
Skipper's Exponential Tumor Growth/Log-Kill Hypothesis
One of the pioneer investigations in tumor growth kinetics was made by Skipper and his colleagues, 3 who described the first model of tumor growth kinetics. Despite its flaws and oversimplified nature, the empiric observations derived from this model underlie many of the tenets in cancer chemotherapy. A conclusion derived from his L1210 mouse leukemia model was the exponential (logarithmic) growth of tumor cells. Doubling time of cancer cells was proposed to be constant, yielding a straight line on a semilog plot (Figure 2 .1). Another conclusion generated from their experiments was the log-kill hypothesis, which proposes that anticancer drugs act with first-order kinetics, and hence, assuming homogeneous sensitivity to the drug, they will eliminate a constant proportion rather than a constant number of tumor cells regardless of the initial size of the tumor; that is, magnitude of tumor cell kill is a logarithmic function.
3 By this a posteriori reasoning, if sufficient drug is given, cure can be achieved when fewer than 1 tumor cell remains. Similarly, therapy against small-volume tumors or micrometastatic disease should be easily successful in effecting cures. However, clinical experience in adjuvant chemotherapy has not borne out this deductive assumption as successfully as hoped.
Gompertzian Model of Tumor Growth
With further studies, it became clear that Skipper's model was oversimplified and applied only to the proliferating segment within the tumor. Some early-stage malignancies, such as testicular germ cell tumor, may behave in such a way when they are composed of proliferating cells highly responsive to chemotherapeutic agents. However, most human solid tumors do not respond to chemotherapy, contrary to what would have been expected if tumor growth was exponential. Rather, the experimental data in human solid tumors support the Gompertzian kinetics of tumor growth, akin to the sigmoid curve seen in microbial kinetics under a controlled environment, where the initial growth phase is steep at smaller volumes, eventually plateauing and decreasing with time once a critical mass is reached 4 (Figure 2 .2). As many anticancer agents are cell cycle specific and are usually most active against cells that are proliferating, a critical factor in drug responsiveness of tumors to cell-cycle-specific drugs depends on the particular phase the tumor is in its growth curve. This model also helps explain why, unless cure was effected, varying degrees of residual tumor volume result in similar relapse-free survival over time.
Norton-Simon Model
In Skipper's model, the exponential growth of tumors is presumed to be homogeneous. The Norton-Simon model takes into account the heterogeneity of a tumor cell population following the Gompertzian growth curve. 5, 6 The log kill would be greater for very small cancers than for larger tumors. However, smaller cancers also regrow faster. The greater fractional kill, such as against micrometastases in the adjuvant setting, is offset by fractional repopulation of tumor cells at the same fast rate. Thus, tumors are difficult to eradicate under this model. As already stated, this model predicts the observation that adjuvant chemotherapy does not have much impact on overall survival, as opposed to the improvement in disease-free survival. Survival can thus be improved only when tumor cell populations are eradicated or rendered 2 D dormant during the early growth phase. Another implication is that effective therapy should be delivered at reduced intervals to maximize the chances of tumor eradication and to minimize tumor regrowth in between cycles of therapy.
Goldie and Coldman Hypothesis
An important corollary to tumor growth is the development of drug resistance resulting from spontaneous mutations that occur with cell proliferation, independent of the resistance inherent to the heterogeneity in cell kinetics described earlier. Goldie and Coldman had hypothesized that this occurs at a rate of 1 of 10 5 cells per gene. 7 If 1 g tumor, the minimum size for detection, contains 10 9 cells, then such a tumor might contain 10 4 clones resistant to any given drug. However, resistance to two drugs would be seen in fewer than 1 cell in a 10-g (10 10 cells) tumor. This idea is consistent with the known observation that combination chemotherapy is more effective than single-agent regimens. Nevertheless, single agents have remained successful in the treatment of certain tumors, such as Burkitt's lymphoma at sizes greater than 1 g. 8 This hypothesis is one basis for the idea that chemotherapy should theoretically be started when tumor burden is smallest, to be effective; concomitant or alternating administration of noncross-resistant drugs is preferred to sequential chemotherapy. However, delaying therapy does not necessarily result in decreased responsiveness in many cases.
9,10 Similarly, administration of chemotherapy preoperatively, although it may be predicted to be more beneficial based on this model, does not confer any significant improvement in the clinical outcomes in resectable early-stage breast cancer. This model also assumes a stepwise development of resistance to individual agents and thus does not account for multidrug resistance patterns.
Tumor cell growth kinetics are complex and poorly understood. There are no available models that accurately describe all aspects of clinical behavior of solid tumors. The heterogeneous genetic abnormalities of different tumors underlie their behavior, making it impossible to make broad predictions.
Chemotherapy Approaches in the Management of Cancers
Cancer chemotherapy has principally been used in the management of advanced or metastatic disease, following failed local therapies, or in disease for which no alternative therapy is effective. Chemotherapy is curative for several advanced human cancers, such as gestational trophoblastic disease, certain hematologic malignancies, or germ cell testicular cancer. However, most common solid tumors are not curable with current chemotherapeutic regimens when metastatic (Table 2 .1).
The roles of chemotherapy are manifold: induction chemotherapy denotes its use as primary therapy when there is no alternative treatment available or subsequently suitable even with tumor response, such as in hematologic malignancies, where disease is systemic. As an adjunct in combined modality therapy, chemotherapy is adjuvant when systemic treatment is applied after the tumor has been controlled by an alternative modality, such as surgery and/or radiotherapy, or neoadjuvant (primary) chemotherapy when localized cancer will otherwise not be optimally managed if systemic chemotherapy is not used before definitive local therapy.
Dose Intensity Versus Dose Density
Multiple laboratory experiments have established the proportionate dose-response curve, such that log kill is greater for the regimen with a higher dose intensity (i.e., by increasing the dose level delivered over a standard time interval). The slope of the curve is often steeper for tumors with a higher growth fraction. This observation underlies one of the principles in cancer chemotherapy-the administration of the highest possible dose of drugs in the shortest possible time intervals. The latter is typically limited by the recovery period of host organ function, such as the gastrointestinal tract and, in particular, the bone marrow, and thus explains the familiar 14-to 28-day intervals between cycles of therapy.
Progress in understanding of tumor growth kinetics has led to the emergence of new concepts in the schedules and 
